BIIB

SEC source: 0001127602-23-005273 · form4.xml · derivative · entry 8

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,770 shares

Expires 2023-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005273 · form4.xml · derivative · entry 7

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,770

Underlying: Common Stock · 1,448 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005273 · form4.xml · derivative · entry 6

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,150

Underlying: Common Stock · 2,575 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 5

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,920

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.

SEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 4

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,657

SEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 3

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,910

SEC source: 0001127602-23-005273 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Off & Corp Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,674

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005272 · form4.xml · derivative · entry 8

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,384 shares

Expires 2023-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005272 · form4.xml · derivative · entry 7

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,384

Underlying: Common Stock · 1,132 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005272 · form4.xml · derivative · entry 6

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,317

Underlying: Common Stock · 2,158 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005272 · form4.xml · nonDerivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,147.0168

F1 · shares: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.

SEC source: 0001127602-23-005272 · form4.xml · nonDerivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,257.0168

SEC source: 0001127602-23-005272 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,805.0168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005272 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,673.0168

SEC source: 0001127602-23-005272 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,321.0168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005270 · form4.xml · derivative · entry 8

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 278 shares

Expires 2023-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005270 · form4.xml · derivative · entry 7

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278

Underlying: Common Stock · 228 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005270 · form4.xml · derivative · entry 6

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,667

Underlying: Common Stock · 833 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 5

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,569.7483

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.

SEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 4

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,830.7483

SEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,897.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,669.7483

SEC source: 0001127602-23-005270 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,931.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005271 · form4.xml · derivative · entry 8

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 553 shares

Expires 2023-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005271 · form4.xml · derivative · entry 7

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 553

Underlying: Common Stock · 453 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005271 · form4.xml · derivative · entry 6

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,030

Underlying: Common Stock · 1,515 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 5

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,488

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.

SEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 4

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,130

SEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,897

SEC source: 0001127602-23-005271 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,359

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005269 · form4.xml · derivative · entry 3

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,514

Underlying: Common Stock · 3,256 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005269 · form4.xml · nonDerivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,896

SEC source: 0001127602-23-005269 · form4.xml · nonDerivative · entry 1

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,001

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005268 · form4.xml · derivative · entry 8

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 416 shares

Expires 2023-02-12

F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005268 · form4.xml · derivative · entry 7

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 416

Underlying: Common Stock · 340 shares

Expires 2023-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This award was granted to the reporting person on February 12, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-23-005268 · form4.xml · derivative · entry 6

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,544

Underlying: Common Stock · 2,271 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022.

SEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 5

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,332.2903

SEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 4

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,497.2903

F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon vesting of shares, as previously disclosed by reporting person on January 27, 2023.

SEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 3

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,034.2903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,694.2903

SEC source: 0001127602-23-005268 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,379.2903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-005267 · form4.xml · derivative · entry 3

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,424

Underlying: Common Stock · 1,211 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 10, 2022 and will vest in three equal installments on each anniversary of the grant date.

SEC source: 0001127602-23-005267 · form4.xml · nonDerivative · entry 2

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,491.3923

SEC source: 0001127602-23-005267 · form4.xml · nonDerivative · entry 1

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,863.3923

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-004582 · form4.xml · derivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,305

Underlying: Common Stock · 6,305 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.

SEC source: 0001127602-23-004581 · form4.xml · derivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,365

Underlying: Common Stock · 2,365 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023.

SEC source: 0001127602-23-004579 · form4.xml · derivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,005

Underlying: Common Stock · 7,005 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.

SEC source: 0001127602-23-004578 · form4.xml · derivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,130

Underlying: Common Stock · 6,130 shares

Expires 2026-02-08

F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023.